On April 2, 2025, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.

The Wilson Sonsini team that represented Edgewise Therapeutics in the transaction included Tony Jeffries, Jennifer Knapp, Rachel Nagashima, Enid Qin, Ashley Slack, Andrew Kim, Julia Minitti, and Grant Margulieux.

For more information, please see Edgewise Therapeutics' news release.